Digital health company Klue announced this week that its latest AI-driven software is a module designed for people with Type I diabetes. The technology features autonomous meal detection capabilities and provides mealtime medication reminders to users, according to the San Francisco, Calif.-based company. The module, which works with hardware like the Apple Watch, also provides […]
Abbott wins FDA nod for FreeStyle Libre’s mobile app
Abbott (NYSE:ABT) said today that it won FDA approval for a mobile app that is designed for the company’s FreeStyle Libre continuous glucose monitoring system. The FreeStyle LibreLink app allows users to capture and view their glucose data in real-time using their mobile phones. Prior to the mobile app, people using Abbott’s FreeStyle Libre CGM had […]
Reva launches Fantom Encore bioresorbable scaffold
Reva Medical (ASX:RVA) said this week that it launched its Fantom Encore bioresorbable, drug-eluting scaffold and that the first person was treated in a post-market trial of the device. The Fantom Encore product is a third-gen coronary bioresorbable scaffold featuring a thin strut profile and Reva’s Tyrocore polymer. Reva noted that the device will be made […]
Mustang Bio studies intraventricular delivery of immunotherapy in Ph1 trial
Mustang Bio (NSDQ:MBIO) said today that it launched a Phase I trial to evaluate the safety and efficacy of intraventricular delivery of CAR T-cells to the brains of people with HER2-positive breast cancer. The 21-patient trial’s primary goal is to determine the recommended dosing regimen for a Phase II trial. Secondary objectives include evaluating the […]
LifeScan releases latest version of diabetes management app
LifeScan said today that it released the latest version of its OneTouch Reveal mobile app. The digital tool is designed to help people with diabetes track their blood sugar levels using their mobile devices and share data with healthcare teams and caregivers. The newest version of LifeScan’s app includes notifications that automatically warn users of […]
Carrot raises $25m for tech-enabled smoking cessation program
Digital health company Carrot said today that it raised $25 million to commercialize its tech-enabled Pivot smoking cessation program. The round was led by Johnson & Johnson‘s (NYSE:JNJ) strategic venture capital arm, JJDC. New York Life Ventures and existing investors Khosla Ventures, Marc Benioff, founder Dr. David Utley and R7 Partners also contributed to the […]
Sanofi leads $50m round for Enable Injections’ on-body drug-delivery platform
Enable Injections said last week that it closed a $50 million Series B round, led by Sanofi (NYSE:SNY), to fund the development of its enFuse on-body drug-delivery system. Previous investors, including the Cleveland Clinic and CincyTech, and private investors also participated in the round. Enable Injections has developed a drug-delivery device that’s designed to deliver doses […]
Clearside Biomedical reports analyses from pivotal trial of eye drug
Clearside Biomedical (NSDQ:CLSD) touted new analyses of data from the company’s Phase III pivotal trial of suprachoroidal CLS-TA in people with uveitic macular edema. The company’s investigational treatment is a suspension of triamcinolone acetonide formulated to be delivered to the back of the eye via the suprachoroidal space. Clearside reported that 40% of people taking its […]
Genentech touts data for refillable eye implant in wet-AMD trial
Roche‘s (OTC:RHHBY) Genentech touted additional positive data last week from a Phase II study of its Port Delivery System, a refillable eye implant designed to deliver ranibizumab to treat wet age-related macular degeneration. The company first reported top-line results from the Phase II Ladder study in July. The implant is intended to allow wet-AMD patients to go […]
GenSight Biologics launches trial for gene therapy, eye device combo
GenSight Biologics (EPA:SIGHT) said today that the first person was treated in a first-in-man trial evaluating GenSight’s gene therapy candidate, GS030-DP, in combination with a wearable optronic visual stimulation device, GS030-MD. Scientists are evaluating the drug-device combination in 18 people with retinitis pigmentosa. The Pioneer Phase I/II trial is an open-label, dose-escalation study designed to assess […]
